152 related articles for article (PubMed ID: 12809971)
1. Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study.
Carroll CA; Coen MM; Rymer MM
Clin Ther; 2003 Apr; 25(4):1248-61. PubMed ID: 12809971
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study.
Björholt I; Andersson FL; Kahan T; Ostergren J
J Intern Med; 2002 Jun; 251(6):508-17. PubMed ID: 12028506
[TBL] [Abstract][Full Text] [Related]
3. Economic impact of ramipril on hospitalization of high-risk cardiovascular patients.
Carroll CA; Coen MM; Piepho RW
Ann Pharmacother; 2003 Mar; 37(3):327-31. PubMed ID: 12639157
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of ramipril treatment for cardiovascular risk reduction.
Malik IS; Bhatia VK; Kooner JS
Heart; 2001 May; 85(5):539-43. PubMed ID: 11303006
[TBL] [Abstract][Full Text] [Related]
6. Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate?
Grover SA; Coupal L; Lowensteyn I
Can J Cardiol; 2008 Apr; 24(4):261-6. PubMed ID: 18401465
[TBL] [Abstract][Full Text] [Related]
7. Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study.
Smith MG; Neville AM; Middleton JC
Intern Med J; 2003; 33(9-10):414-9. PubMed ID: 14511193
[TBL] [Abstract][Full Text] [Related]
8. Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model.
Grover SA; Coupal L; Lowensteyn I
Am J Cardiovasc Drugs; 2007; 7(6):441-8. PubMed ID: 18076211
[TBL] [Abstract][Full Text] [Related]
9. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.
Lamy A; Yusuf S; Pogue J; Gafni A;
Circulation; 2003 Feb; 107(7):960-5. PubMed ID: 12600907
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events.
Capri S; Perlini S
Curr Med Res Opin; 2005 Jun; 21(6):913-21. PubMed ID: 16003858
[TBL] [Abstract][Full Text] [Related]
11. Effect of long-term therapy with ramipril in high-risk women.
Lonn E; Roccaforte R; Yi Q; Dagenais G; Sleight P; Bosch J; Suhan P; Micks M; Probstfield J; Bernstein V; Yusuf S;
J Am Coll Cardiol; 2002 Aug; 40(4):693-702. PubMed ID: 12204499
[TBL] [Abstract][Full Text] [Related]
12. The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.
Lamy A; Wang X; Gao P; Tong W; Gafni A; Dans A; Avezum A; Ferreira R; Young J; Yusuf S; Teo K;
J Med Econ; 2011; 14(6):792-7. PubMed ID: 21981559
[TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness analysis of Ramipril treatment of patients at high-risk of cardiovascular events in Spain].
Hart WM; Rubio-Terrés C; Margalet Fernández I; González Juanatey JR
An Med Interna; 2002 Oct; 19(10):515-20. PubMed ID: 12481494
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: a Swiss perspective.
Aurbach A; Russ W; Battegay E; Bucher HC; Brecht JG; Schädlich PK; Sendi P
Swiss Med Wkly; 2004 Jul; 134(27-28):399-405. PubMed ID: 15389357
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomic impact of HOPE.
Ostergren JB; Björholt I; Andersson F; Kahan T
Int J Clin Pract Suppl; 2001 Jan; (117):19-21. PubMed ID: 11715354
[TBL] [Abstract][Full Text] [Related]
16. The HOPE Study (Heart Outcomes Prevention Evaluation).
Sleight P
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
[TBL] [Abstract][Full Text] [Related]
17. HOPE study impact on ACE inhibitors use.
Hemels ME; Bennett HA; Bonari L; Han D; Traverso ML; Einarson TR
Ann Pharmacother; 2003 May; 37(5):640-5. PubMed ID: 12708937
[TBL] [Abstract][Full Text] [Related]
18. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
Gerstein HC
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on ramipril in the prevention of cardiovascular outcomes.
Warner GT; Perry CM
Am J Cardiovasc Drugs; 2003; 3(2):113-6. PubMed ID: 14727938
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.
Schädlich PK; Brecht JG; Brunetti M; Pagano E; Rangoonwala B; Huppertz E
Pharmacoeconomics; 2001; 19(5 Pt 1):497-512. PubMed ID: 11465309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
